Modern management of genital ulcer disease-frappez fort et frappez vite

Sexually Transmitted Diseases

Volumn 37, Issue 8, 2010, Pages 494-496

  Lewis, David ^a,b,c,d,e  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e African Regional Office of the International Union Against Sexually Transmitted Infections   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FAMCICLOVIR; VALACICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EDITORIAL; GENITAL HERPES; GENITAL ULCER; HEALTH SURVEY; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; RANDOMIZED CONTROLLED TRIAL; SEXUALLY TRANSMITTED DISEASE;

ACYCLOVIR; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HERPES GENITALIS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; ULCER; WORLD HEALTH ORGANIZATION;

EID: 77955177330     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3181e2d156     Document Type: Editorial

References (26)

1. Paz-Bailey G, Ramaswamy M, Hawkes SJ, et al. Herpes simplex virus type 2: Epidemiology and management options in developing countries. Sex Transm Infect 2007; 83:16-22.
2. Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007; 370: 2127-2137.
3. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ. 2008; 86:805-812, A.
4. Wald A. Synergistic interactions between herpes simplex virus type-2 and human immunodeficiency virus epidemics. Herpes 2004; 11:70-76.
5. Corey L, Wald A, Celum CL, et al. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: A review of two overlapping epidemics. J Acquir Immun Defic Syndr 2004; 35: 435-445.
6. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149-1153.
7. Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: A systematic review and meta-analysis. Sex Transm Dis 2008; 35:946-959.
8. Schacker T, Zeh J, Hu H, et al. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002; 186: 1718-1725.
9. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427-439.
10. World Health Organisation. Guidelines for the management of sexually transmitted infections. 2003. Available at: http://www.who.int/reproductive- health/publications/mngt-stis/index.html. Accessed April 27, 2009.
11. Corbell C, Stergachis A, Ndowa F, et al. Genital ulcer disease treatment policies and access to acyclovir in eight sub-Saharan African countries. Sex Transm Dis. In press.
12. National Department of Health. First line comprehensive management and control of sexually transmitted infections (STIs): Protocol for the management of a person with a sexually transmitted infection according to the Essential Drug List. Pretoria, South Africa: National Department of Health, 2008, 1-18.
13. Essential Drugs Programme. Primary Health Care Standard Treatment Guidelines and Essential Medicines List 2008. 4th ed. Pretoria, South Africa: The National Department of Health, 2008.
14. Paz-Bailey G, Sternberg M, Puren AJ, et al. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: A randomized, controlled trial. J Infect Dis 2009; 200:1039-1049.
15. Lewis DA, Marumo E. Revision of the national guideline for first-line comprehensive management and control of sexually transmitted infections: What's new and why? S Afr J Epid Infect 2009; 24:6-9.
16. Patel R, Rutland E. Has episodic treatment of recurrent genital herpes come of age? Int J STD AIDS 2007; 18:437-439.
17. Mayaud P, Legoff J, Weiss HA, et al. Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: A randomized placebo-controlled trial. J Infect Dis 2009; 200:216-226.
18. Wald A, Carrell D, Remington M, et al. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 2002; 34:944-948.
19. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: A shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis 2002; 34:958-962.
20. Strand A, Patel R, Wulf HC, et al. Aborted genital herpes simplex virus lesions: Findings from a randomised controlled trial with valaciclovir. Sex Transm Infect 2002; 78:435-439.
21. Aoki FY, Tyring S, Diaz-Mitoma F, et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: A randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2006; 42:8-13.
22. Bodsworth N, Bloch M, McNulty A, et al. 2-day versus 5-day famciclovir as treatment of recurrences of genital herpes: Results of the FaST study. Sex Health 2008; 5:219-225.
23. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. 2006. Available at: http://www. cdc.gov/std/treatment/ 2006/toc.htm. Accessed March, 21, 2010
24. Spruance SL, Tyring SK, DeGregorio B, et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med 1996; 156:1729-1735.
25. Tyring SK, Douglas JM Jr, Corey L, et al. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group. Arch Dermatol 1998; 134:185-191.
26. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: A randomised, double blind clinical trial. International Valaciclo-vir HSV Study Group. Genitourin Med 1997; 73:110-116.